OR WAIT null SECS
July 07, 2025
Article
The first half of 2025 recap for hepatology spotlights FDA approvals, clinical trial updates, and the 1-year anniversary of resmetirom.
July 03, 2025
The Q2 recap for hepatology spotlights regulatory approvals, clinical trial updates, and the launch of HCPLive’s flagship hepatology podcast.
July 02, 2025
This FDA News Month in Review provides a round-up of regulatory decisions from June 2025.
July 01, 2025
The month in review spotlights hepatic regulatory news, new clinical trial data, and novel research about liver disease risk factors.
June 30, 2025
An audio recap of the top 5 stories in healthcare news from the week of 06/16-06/22
Stay updated with the latest healthcare breakthroughs, including new phase 2/3 clinical trial data and an FDA approval, in this week's essential news roundup.
June 27, 2025
Patients with cirrhosis receiving diuretics and SGLT-2 inhibitors experienced lower rates of serious liver events than those not taking SGLT-2 inhibitors.
June 26, 2025
Positive topline results show the trial met its primary endpoint for MASH resolution and fibrosis improvement, with significant weight loss effects without plateauing.
June 25, 2025
Topline data from the phase 1b study for the final 400 mg dose cohort demonstrate favorable safety, tolerability, and pharmacokinetics similar to the 150 mg dose cohort.
June 24, 2025
A recent cross-sectional analysis has estimated the size of the American population with both MASLD and T2DM eligible for treatment.
